Rosuvastatin (all strengths): Supply issue

Supply issue Active

Viatris, the supplier, advises that due to disruptions at the factory, there is limited supply of Viatris brand rosuvastatin tablets.

30 June 2026 | Rosuvastatin access widening

We have announced that rosuvastatin will be funded for anyone who needs it from 1 October 2026. 

Decision to open list rosuvastatin tablets

Affected product

Due to disruptions at the factory Rosuvastatin Viatris tablets are not available. 

Schedule listings for rosuvastatin(external link)

People who take rosuvastatin

If you take rosuvastatin, you may notice that your usual tablet looks different or comes in different packaging.

Same active ingredient, in the same amount 

Please be assured, whether it's Viatris, Sandoz, or Mylan, your medicine has the same amount of active ingredient and is designed to work in your body the same way. 

We understand that frequent brand changes can be disruptive. These are necessary to ensure you can continue to access your medicine. 

Medsafe approved

Medsafe, the government agency responsible for medicine safety, has reviewed these medicines and approved them for sale in New Zealand. They have made sure they meet New Zealand standards of safety, quality, and effectiveness. 

Alternative brands

The pack size for Rosuvastatin Mylan remains unchanged. The subsidy is the same as for Rosuvastatin Viatris. The Mylan brand is available for wholesalers to order from Viatris.

Full details, including Pharmacodes, are listed in the Schedule.

Schedule listings for rosuvastatin(external link)

Medsafe approved

All brands have received Medsafe approval for use in New Zealand, so can be prescribed and dispensed as usual. The datasheet and CMI sheet are available on Medsafe's website.

Datasheet for Rosuvastatin Mylan [PDF, 134 MB](external link)

CMI for Rosuvastatin Mylan Film coated tablet [PDF, 341 MB](external link)

Expected resupply 2026

Viatris will continue to supply the Mylan brand until the Viatris brand is available again. This is anticipated for September 2026.

Who to contact

If you have questions about this issue, email enquiry@pharmac.govt.nz

Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.

Sign up to our email list for regular emails about supply issues and more(external link)